Literature DB >> 9927168

Octreotide in the treatment of the hepatorenal syndrome in cirrhotic patients.

F Kaffy, C Borderie, C Chagneau, M P Ripault, I Larzillière, C Silvain, M Beauchant.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1999        PMID： 9927168     DOI： 10.1016/s0168-8278(99)80025-7

Source DB:  PubMed          Journal:  J Hepatol        ISSN： 0168-8278            Impact factor:   25.083


× No keyword cloud information.
  6 in total

Review 1.  The hepatorenal syndrome.

Authors:  L Dagher; K Moore
Journal:  Gut       Date:  2001-11       Impact factor: 23.059

Review 2.  Hepatorenal syndrome.

Authors:  Sharon Turban; Paul J Thuluvath; Mohamed G Atta
Journal:  World J Gastroenterol       Date:  2007-08-14       Impact factor: 5.742

3.  Therapeutic response to vasoconstrictors in hepatorenal syndrome parallels increase in mean arterial pressure: a pooled analysis of clinical trials.

Authors:  Juan Carlos Q Velez; Paul J Nietert
Journal:  Am J Kidney Dis       Date:  2011-09-29       Impact factor: 8.860

4.  Long term outcome after transjugular intrahepatic portosystemic stent-shunt in non-transplant cirrhotics with hepatorenal syndrome: a phase II study.

Authors:  K A Brensing; J Textor; J Perz; P Schiedermaier; P Raab; H Strunk; H U Klehr; H J Kramer; U Spengler; H Schild; T Sauerbruch
Journal:  Gut       Date:  2000-08       Impact factor: 23.059

5.  Treatment for hepatorenal syndrome in people with decompensated liver cirrhosis: a network meta-analysis.

Authors:  Lawrence Mj Best; Suzanne C Freeman; Alex J Sutton; Nicola J Cooper; Eng-Loon Tng; Mario Csenar; Neil Hawkins; Chavdar S Pavlov; Brian R Davidson; Douglas Thorburn; Maxine Cowlin; Elisabeth Jane Milne; Emmanuel Tsochatzis; Kurinchi Selvan Gurusamy
Journal:  Cochrane Database Syst Rev       Date:  2019-09-12

6.  Protocol for a prospective double-blind, randomised, placebo-controlled feasibility trial of octreotide infusion during liver transplantation.

Authors:  Jeremy Fabes; Gareth Ambler; Bina Shah; Norman R Williams; Daniel Martin; Brian R Davidson; Michael Spiro
Journal:  BMJ Open       Date:  2021-12-02       Impact factor: 2.692
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.